2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Interventions
Specimen Handling
655
pembrolizumab
608
Magnetic Resonance Spectroscopy
561
Carboplatin
449
Cisplatin
398
Cyclophosphamide
396
Biopsy
380
Nivolumab
325
Paclitaxel
323
Gemcitabine
317
Radiotherapy
298
Bevacizumab
248
Dexamethasone
223
fludarabine
215
Docetaxel
202
durvalumab
195
Oxaliplatin
189
venetoclax
186
atezolizumab
183
Fluorouracil
177
Rituximab
176
Pemetrexed
173
Capecitabine
170
Radiation
168
Doxorubicin
166
Radiosurgery
161
Ipilimumab
147
Etoposide
142
Leucovorin
140
Lenalidomide
139
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
SGN-LIV1A
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT03424005
2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2
Recruiting
792 enrolled